Interim Report 3rd quarter 2013/14 (1 June 2013 - 28

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Interim Report 3rd quarter 2013/14 (1 June 2013 - 28 February 2014)

Q3 HIGHLIGHTS

“In the third quarter we saw signs of improvement in our European business, which was driven by strong demand for our newly launched speakers in particular and AV products in general. With the successful launch of new products and with a strong pipeline of new products in the coming quarters, we believe that the improvements in our European AV business will continue. Our Automotive business continued on a solid trajectory, whereas the B&O PLAY revenue saw a set-back due to the focus on AV activities in the B1 stores and a too low level of new product introductions”, says CEO Tue Mantoni.

  • The Group’s revenue was DKK 675 million for the third quarter of the 2013/14 financial year compared to revenue of DKK 655 million in the same period last year.
  • The B2C business recorded revenue of DKK 528 million in the third quarter of the 2013/14 financial year compared to DKK 524 million in the same period last year. The AV segment grew by 12 per cent whereas B&O PLAY decreased by 25 per cent. The same quarter last year was positively affected by the DKK 25 million build-up of inventory to the dedicated B&O PLAY shop-in-shops in China.
  • B2C revenue in Europe increased by 17 per cent in the third quarter compared to the same quarter last year. The B2C revenue in BRIC markets decreased by 36 per cent compared to the same quarter last year which was affected by the DKK 25 million build-up of inventory mentioned above. North America decreased by 14 per cent, and revenue in Rest of world decreased by 22 per cent.
  • The B2B business recorded revenue of DKK 152 million in the third quarter of the 2013/14 financial year compared to revenue of DKK 131 million in the same period last year. Automotive grew by 10 per cent.
  • The Group’s gross margin for the third quarter of the 2013/14 financial year was 42.7 per cent compared to 34.9 per cent in the same period last year, and on level with the 42.7 per cent in the second quarter of  the financial year 2013/14. The low gross margin in the same quarter last year was mainly related to an adverse effect from indirect production costs due to reduction in inventory levels. The improved gross margin is also a result of higher margins on new products in both the AV and the B&O PLAY segments.
  • Capacity costs were DKK 315 million in the third quarter, compared to DKK 343 million in the third quarter last year. Distribution and marketing costs have increased by DKK 6 million compared to the same quarter last year due to increased marketing activities and take-over of distribution in China. R&D costs decreased by DKK 22 million compared to the same quarter last year but were on level with the previous quarters.
  • Administration costs were positively affected by a non-recurring gain of approximately DKK 11 million relating to a sale and leaseback of the land and production facilities previously owned by Bang & Olufsen s.r.o. in the Czech Republic.
  • Earnings before interest and tax for the third quarter of the 2013/14 financial year were negative DKK 28 million compared to negative DKK 114 million in the same quarter last year.
  • The Group’s net working capital was DKK 560 million at the end of the third quarter of the 2013/14 financial year, compared to DKK 708 million at the end of the third quarter last year, and DKK 630 million at the end of the second quarter of the 2013/14 financial year.
  • Free cash flow in the third quarter was DKK 94 million compared to DKK 92 million in the same period last year. The free cash flow was positively impacted by DKK 79 million from the sale of the land and  production facilities owned by Bang & Olufsen s.r.o. in the Czech Republic. The same period last year was positively impacted by a significant reduction in net working capital.
  • On a year-to-date basis, for the first nine months of the 2013/14 financial year, the Group’s total revenue was DKK 2,063 million against DKK 2,074 million last year, corresponding to a decrease of 1 per cent. Earnings before interest and tax for the first nine months of the 2013/14 financial year were negative DKK 61 against negative DKK 149 million last year. The free cash flow in the first nine months of the 2013/14 financial year was negative at DKK 28 million compared to negative DKK 261 million last year.
  • During the third quarter Executive Vice President and CFO Henning Bejer Beck resigned from his position at Bang & Olufsen. He will continue in his position at Bang & Olufsen until the end of July 2014. The search for a new CFO has been initiated.
  • The Group’s expectations to the 2013/14 financial year remain unchanged.

Any enquiries about this announcement can be addressed to:

CEO, Tue Mantoni, tel.: +45 9684 5000

CFO, Henning Bejer Beck, tel.: +45 9684 5000

Investors, Claus Højmark Jensen, tel: +45 2325 1067

A webcast will be hosted on 11 April 2014 at 10.00 CET. Access to the webcast is obtained through our home page www.bang-olufsen.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSyent Inc. to Announce Q3 Financial Results This Month

Updated Category News Views 189

BioSyent Inc. to Announce Q3 Financial Results BioSyent Inc., a prominent player in the specialty pharmaceutical industry, is preparing to release its financial results for the third quarter and year-to-date period. This important announcement is scheduled for November 20, prior to the market opening. The report will cover the company's performance for the three and nine...

Continue Reading
Dr. Ryan Egeland Joins Solventum as Chief Medical Officer

Updated Category News Views 381

Solventum Welcomes Dr. Ryan Egeland as New CMO Solventum, a pioneering healthcare company, recently announced the appointment of Dr. Ryan Egeland, MD, as their Chief Medical Officer. In this significant role, Dr. Egeland will lead the Global Medical and Clinical Affairs team, amplifying clinician and patient voices within the organization. Fostering Collaboration and...

Continue Reading
MiningToken Revolutionizes Cryptocurrency With AI Power

Updated Category News Views 186

Introducing MiningToken's Innovative AI Cloud Mining Service Bitcoin and Ethereum are experiencing remarkable market dynamics as Bitcoin persists in a bullish trend and Ethereum has gained notable ground recently. As global interest in cryptocurrencies grows, effective mining strategies are crucial for profitability. Amidst rising operational costs, many individuals seek...

Continue Reading
Saluda Medical's EVA™ Sensing Technology Approved in Europe

Updated Category News Views 111

Saluda Medical Achieves Regulatory Milestone with EVA™ Technology Saluda Medical, Inc. (ASX:SLD) has made significant strides in the medical device industry by achieving CE certification for its next-generation EVA™ Sensing Technology. This advancement not only marks a major endorsement in Europe but also is recognized in Australia. Following FDA approval in December...

Continue Reading
ReadPartner Inc. Unveils Revolutionary AI Tool to Combat Misinformation

Updated Category News Views 291

ReadPartner Inc. Launches AI Feature to Tackle Misinformation ReadPartner Inc., a leader in AI-driven media intelligence solutions, is excited to announce the upcoming launch of a groundbreaking digital security feature named ProfileScreen. This innovative tool aims to address the pressing issue of misinformation that plagues social media platforms. The ProfileScreen...

Continue Reading